Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells

Liu,Tao; Fang,Zhihai; Wang,Gang; Shi,Mingjun; Wang,Xiao; Jiang,Kun; Yang,Zhonghua; Cao,Rui; Tao,Huangheng; Wang,Xinghuan; Zhou,Jiajie

doi:10.3892/ol.2015.3854

Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells

Authors:
- Tao Liu
- Zhihai Fang
- Gang Wang
- Mingjun Shi
- Xiao Wang
- Kun Jiang
- Zhonghua Yang
- Rui Cao
- Huangheng Tao
- Xinghuan Wang
- Jiajie Zhou
View Affiliations

Affiliations: Department of Urology, Jingzhou Central Hospital, Jingzhou, Hubei 434020, P.R. China, Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Key Laboratory for Oral Biomedicine of Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei 430079, P.R. China
Published online on: November 2, 2015 https://doi.org/10.3892/ol.2015.3854
Pages: 182-188
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the anti‑tumor activity of N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amide (BCTC), a potent and specific inhibitor of transient receptor potential cation channel subfamily M member 8 (TRPM8) in prostate cancer (PCa) DU145 cells. TRPM8 expression in DU145 and normal prostate PNT1A cells was detected by reverse transcription polymerase chain reaction and western blot analysis. The effect of BCTC on DU145 cells was analyzed by flow cytometry analysis, and MTT, scratch motility and Transwell invasion assays. The molecular mechanism through which BCTC acts was investigated by western blot analysis. TRPM8 expression was increased in DU145 cells compared with PNT1A cells at the mRNA and protein levels. The present study provided evidence that inhibition of TRPM8 by BCTC reduced the viability of DU145 cells, but not PNT1A cells. In addition, BCTC inhibited cell cycle progression, migration and invasion in DU145 cells. Cell cycle‑associated proteins, including phosphorylated protein kinase B, cyclin D1, cyclin dependent kinase (CDK) 2 and CDK6 were downregulated by BCTC, while phosphorylated glycogen synthase kinase 3β was upregulated. However, investigations in the present study revealed that BCTC failed to trigger apoptosis in DU145 cells. In addition, in BCTC‑treated DU145 cells, phosphorylated extracellular signal‑regulated kinase 1/2 was downregulated substantially while phosphorylated p38 (p‑p38) and phosphorylated c‑Jun N‑terminal kinases (p‑JNK) were upregulated. The anti‑proliferative activity of BCTC on DU145 cells was attenuated by p38 and JNK‑specific inhibitors, suggesting that MAPK pathways are involved. Overall, the TRPM8 specific antagonist BCTC demonstrated excellent anti‑tumor activity in PCa DU145 cells, and therefore has the potential to become a targeted therapeutic strategy against PCa.

View Figures

View References

1	Akaza H: Asian trends in primary androgen depletion therapy on prostate cancer. Cancer Biol Med. 10:187–191. 2013.PubMed/NCBI
2	Baade PD, Youlden DR, Cramb SM, Dunn J and Gardiner RA: Epidemiology of prostate cancer in the Asia-Pacific region. Prostate Int. 1:47–58. 2013. View Article : Google Scholar : PubMed/NCBI
3	Rosenthal SA and Sandler HM: Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol. 7:31–38. 2010. View Article : Google Scholar : PubMed/NCBI
4	Chen Y, Clegg NJ and Scher HI: Anti-androgens and androgen-depleting therapies in prostate cancer: New agents for an established target. Lancet Oncol. 10:981–991. 2009. View Article : Google Scholar : PubMed/NCBI
5	Damber JE and Aus G: Prostate cancer. Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
6	Taplin ME: Drug insight: Role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol. 4:236–244. 2007. View Article : Google Scholar : PubMed/NCBI
7	Sullivan GF, Amenta PS, Villanueva JD, Alvarez CJ, Yang JM and Hait WN: The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res. 4:1393–1403. 1998.PubMed/NCBI
8	Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG and Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 10:33–39. 2004. View Article : Google Scholar : PubMed/NCBI
9	Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW and Scher HI: Prostate cancer cell cycle regulators: Response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 91:1869–1876. 1999. View Article : Google Scholar : PubMed/NCBI
10	Wissenbach U, Niemeyer BA and Flockerzi V: TRP channels as potential drug targets. Biol Cell. 96:47–54. 2004. View Article : Google Scholar : PubMed/NCBI
11	Prevarskaya N, Zhang L and Barritt G: TRP channels in cancer. Biochim Biophys Acta. 1772:937–946. 2007. View Article : Google Scholar : PubMed/NCBI
12	Tsavaler L, Shapero MH, Morkowski S and Laus R: Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 61:3760–3769. 2001.PubMed/NCBI
13	Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, et al: Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 63:4196–4203. 2003.PubMed/NCBI
14	Okamoto Y, Ohkubo T, Ikebe T and Yamazaki J: Blockade of TRPM8 activity reduces the invasion potential of oral squamous carcinoma cell lines. Int J Oncol. 40:1431–1440. 2012.PubMed/NCBI
15	Yee NS, Brown RD, Lee MS, Zhou W, Jensen C, Gerke H and Yee RK: TRPM8 ion channel is aberrantly expressed and required for preventing replicative senescence in pancreatic adenocarcinoma: Potential role of TRPM8 as a biomarker and target. Cancer Biol Ther. 13:592–599. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhang L and Barritt GJ: Evidence that TRPM8 is an androgen-dependent Ca²⁺ channel required for the survival of prostate cancer cells. Cancer Res. 64:8365–8373. 2004. View Article : Google Scholar : PubMed/NCBI
17	Valero ML, de Queiroz Mello F, Stühmer W, Viana F and Pardo LA: TRPM8 ion channels differentially modulate proliferation and cell cycle distribution of normal and cancer prostate cells. PloS One. 7:e518252012. View Article : Google Scholar : PubMed/NCBI
18	Madrid R, Donovan-Rodríguez T, Meseguer V, Acosta MC, Belmonte C and Viana F: Contribution of TRPM8 channels to cold transduction in primary sensory neurons and peripheral nerve terminals. J Neurosci. 26:12512–12525. 2006. View Article : Google Scholar : PubMed/NCBI
19	Mergler S, Mertens C, Valtink M, Reinach PS, Székely VC, Slavi N, Garreis F, Abdelmessih S, Türker E, Fels G and Pleyer U: Functional significance of thermosensitive transient receptor potential melastatin channel 8 (TRPM8) expression in immortalized human corneal endothelial cells. Exp Eye Res. 116:337–439. 2013. View Article : Google Scholar : PubMed/NCBI
20	Alao JP: The regulation of cyclin D1 degradation: Roles in cancer development and the potential for therapeutic invention. Mol Cancer. 6:242007. View Article : Google Scholar : PubMed/NCBI
21	Trudeau ME: Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol. 6:443–457. 1996.PubMed/NCBI
22	Kulkarni P: TRPM8 and prostate cancer: To overexpress or repress, that is the question-comment on “Effects of TRPM8 on proliferation and motility of prostate cancer PC-3 cells” by Yang ZH et al in Asian Journal of Andrology. Asian J Androl. 11:150–151. 2009. View Article : Google Scholar : PubMed/NCBI
23	Flourakis M and Prevarskaya N: Insights into Ca²⁺ homeostasis of advanced prostate cancer cells. Biochim Biophys Acta. 1793:1105–1109. 2009. View Article : Google Scholar : PubMed/NCBI
24	Yang ZH, Wang XH, Wang HP and Hu LQ: Effects of TRPM8 on the proliferation and motility of prostate cancer PC-3 cells. Asian J Androl. 11:157–165. 2009. View Article : Google Scholar : PubMed/NCBI
25	Wang Y, Wang X, Yang Z, Zhu G, Chen D and Meng Z: Menthol inhibits the proliferation and motility of prostate cancer DU145 cells. Pathol Oncol Res. 18:903–910. 2012. View Article : Google Scholar : PubMed/NCBI
26	Mälkiä A, Madrid R, Meseguer V, de la Peña E, Valero M, Belmonte C and Viana F: Bidirectional shifts of TRPM8 channel gating by temperature and chemical agents modulate the cold sensitivity of mammalian thermoreceptors. J Physiol. 581:155–174. 2007. View Article : Google Scholar : PubMed/NCBI
27	Valero M, Morenilla-Palao C, Belmonte C and Viana F: Pharmacological and functional properties of TRPM8 channels in prostate tumor cells. Pflugers Arch. 461:99–114. 2011. View Article : Google Scholar : PubMed/NCBI
28	Parsons JT, Slack-Davis J, Tilghman R and Roberts WG: Focal adhesion kinase: Targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res. 14:627–632. 2008. View Article : Google Scholar : PubMed/NCBI
29	Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE and Parsons JT: Alterations in the focal adhesion kinase/Src signal transduction pathway corassociate with increased migratory capacity of prostate carcinoma cells. Oncogene. 20:1152–1163. 2001. View Article : Google Scholar : PubMed/NCBI
30	Page-McCaw A, Ewald AJ and Werb Z: Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 8:221–233. 2007. View Article : Google Scholar : PubMed/NCBI
31	MacCorkle RA and Tan TH: Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys. 43:451–461. 2005. View Article : Google Scholar : PubMed/NCBI